Manufacturing & supply · first seen 19h ago, updated 19h ago
Boehringer Ingelheim offloads Shanghai CDMO to local antibody developer
Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established biologics production base for its lead antibody drug candid…
Summary from Fierce Pharma - Pharma.
Coverage 1 article · 1 outlet
-
Fierce Pharma - PharmaBoehringer Ingelheim offloads Shanghai CDMO to local antibody developer